 <h1>Benznidazole Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to benznidazole: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, benznidazole may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking benznidazole:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>painful or difficult urination</li>
<li>rash</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Burning, numbness, tingling, or painful sensations</li>
<li>headache</li>
<li>tremors</li>
<li>unsteadiness or awkwardness</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding gums</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>blood in the urine or stools</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>difficulty in moving</li>
<li>general tiredness and weakness</li>
<li>inability to concentrate</li>
<li>itching</li>
<li>light-colored stools</li>
<li>muscle pain or stiffness</li>
<li>nausea</li>
<li>pain, swelling, or redness in the joints</li>
<li>pinpoint red spots on the skin</li>
<li>red, irritated eyes</li>
<li>seizures</li>
<li>swelling of the eyelid, arms, or legs</li>
<li>swollen, painful, or tender lymph glands in the neck, armpit, or groin</li>
<li>temporary disorientation</li>
<li>temporary loss of memory</li>
<li>trouble sleeping</li>
<li>upper right abdominal pain</li>
<li>vomiting</li>
<li>yellow eyes and skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of benznidazole may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Decreased appetite</li>
<li>decreased weight</li>
<li>stomach pain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bone pain</li>
<li>dry mouth</li>
<li>loss of sense of taste</li>
<li>loss of strength</li>
<li>muscle aching or cramping</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to benznidazole: oral tablet</i></p><h3>General</h3><p>This drug was used in 55 pediatric patients (aged 6 to 12 years) and 64 pediatric patients (aged 7 to 12 years) during 2 controlled trials and 37 pediatric patients (aged 2 to 12 years) in an uncontrolled trial; each patient had chronic indeterminate Chagas disease.</p>
<p></p>
<p>In 1 controlled trial, this drug was discontinued due to at least 1 side effect in 5 of 55 patients; such side effects included abdominal pain, nausea, vomiting, rash, decreased appetite, headache, and elevated transaminases.  The most commonly reported side effects in this trial were abdominal pain, rash, decreased weight, and headache.</p>
<p></p>
<p>In the uncontrolled trial, rash, leukopenia, urticaria, eosinophilia, decreased appetite, and neutropenia were reported in 6 of 19 pediatric patients (aged 2 to 6 years); such side effects were similar to those reported in the overall population of 37 patients.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (up to 25%)</p>
<p><b>Common</b> (1% to 10%): Nausea, vomiting, diarrhea</p>
<p><b>Postmarketing reports</b>: Epigastric pain, dry mouth<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Extensive skin reactions (such as rash [maculopapular, pruritic macules, eczema, pustules, erythematous, generalized, allergic dermatitis, exfoliative dermatitis]) have been reported.  Most cases occurred after about 10 days of therapy; most rashes resolved with discontinuation of therapy.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Rash (16%), urticaria (16%), skin lesions (11%)</p>
<p><b>Frequency not reported</b>: Severe skin and soft tissue reactions, serious skin and subcutaneous disorders (including eosinophilic drug reaction), extensive skin reactions (such as rash [maculopapular, pruritic macules, eczema, pustules, allergic dermatitis])</p>
<p><b>Postmarketing reports</b>: Maculopapular cutaneous eruptions, erythematous plaques, generalized rash, erythematous rash, pruritic rash, blistering eruptions, peeling skin, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, drug reaction with eosinophilia and systemic symptoms<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (16%), eosinophilia (16%), neutropenia (16%)</p>
<p><b>Frequency not reported</b>: Hematological manifestations of bone marrow depression (such as neutropenia, thrombocytopenia, anemia, leukopenia)</p>
<p><b>Postmarketing reports</b>: Lymphadenopathy, thrombocytopenia, granulocytopenia, agranulocytosis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Anorexia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Decreased weight (13%)</p>
<p><b>Frequency not reported</b>: Genotoxicity</p>
<p><b>Postmarketing reports</b>: Fever, asthenia, fatigue, generalized edema, edema in the extremities, elevated alkaline phosphatase<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, peripheral neuropathy, tremor</p>
<p><b>Postmarketing reports</b>: Paresthesia, hypoesthesia, headaches, convulsions, inability to concentrate, temporary amnesia, ageusia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated transaminases</p>
<p><b>Postmarketing reports</b>: Hepatitis, toxic hepatitis, elevated bilirubin<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia</p>
<p><b>Postmarketing reports</b>: Myalgia, musculoskeletal pain, migratory arthritis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Postmarketing reports</b>: Insomnia, temporary disorientation<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Eyelid edema<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Benznidazole (benznidazole)." Everett Laboratories Inc, West Orange, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about benznidazole</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antibiotics</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Benznidazole &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Trypanosomiasis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to benznidazole: oral tablet</i></p><h3>General</h3><p>This drug was used in 55 pediatric patients (aged 6 to 12 years) and 64 pediatric patients (aged 7 to 12 years) during 2 controlled trials and 37 pediatric patients (aged 2 to 12 years) in an uncontrolled trial; each patient had chronic indeterminate Chagas disease.</p><p></p><p>In 1 controlled trial, this drug was discontinued due to at least 1 side effect in 5 of 55 patients; such side effects included abdominal pain, nausea, vomiting, rash, decreased appetite, headache, and elevated transaminases.  The most commonly reported side effects in this trial were abdominal pain, rash, decreased weight, and headache.</p><p></p><p>In the uncontrolled trial, rash, leukopenia, urticaria, eosinophilia, decreased appetite, and neutropenia were reported in 6 of 19 pediatric patients (aged 2 to 6 years); such side effects were similar to those reported in the overall population of 37 patients.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (up to 25%)</p><p><b>Common</b> (1% to 10%): Nausea, vomiting, diarrhea</p><p><b>Postmarketing reports</b>: Epigastric pain, dry mouth<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Extensive skin reactions (such as rash [maculopapular, pruritic macules, eczema, pustules, erythematous, generalized, allergic dermatitis, exfoliative dermatitis]) have been reported.  Most cases occurred after about 10 days of therapy; most rashes resolved with discontinuation of therapy.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Rash (16%), urticaria (16%), skin lesions (11%)</p><p><b>Frequency not reported</b>: Severe skin and soft tissue reactions, serious skin and subcutaneous disorders (including eosinophilic drug reaction), extensive skin reactions (such as rash [maculopapular, pruritic macules, eczema, pustules, allergic dermatitis])</p><p><b>Postmarketing reports</b>: Maculopapular cutaneous eruptions, erythematous plaques, generalized rash, erythematous rash, pruritic rash, blistering eruptions, peeling skin, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, drug reaction with eosinophilia and systemic symptoms<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (16%), eosinophilia (16%), neutropenia (16%)</p><p><b>Frequency not reported</b>: Hematological manifestations of bone marrow depression (such as neutropenia, thrombocytopenia, anemia, leukopenia)</p><p><b>Postmarketing reports</b>: Lymphadenopathy, thrombocytopenia, granulocytopenia, agranulocytosis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (up to 16%)</p><p><b>Common</b> (1% to 10%): Anorexia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Decreased weight (13%)</p><p><b>Frequency not reported</b>: Genotoxicity</p><p><b>Postmarketing reports</b>: Fever, asthenia, fatigue, generalized edema, edema in the extremities, elevated alkaline phosphatase<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, peripheral neuropathy, tremor</p><p><b>Postmarketing reports</b>: Paresthesia, hypoesthesia, headaches, convulsions, inability to concentrate, temporary amnesia, ageusia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated transaminases</p><p><b>Postmarketing reports</b>: Hepatitis, toxic hepatitis, elevated bilirubin<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia</p><p><b>Postmarketing reports</b>: Myalgia, musculoskeletal pain, migratory arthritis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Postmarketing reports</b>: Insomnia, temporary disorientation<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Eyelid edema<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Benznidazole (benznidazole)." Everett Laboratories Inc, West Orange, NJ. </p><h2>More about benznidazole</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antibiotics</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Benznidazole &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Trypanosomiasis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>